HHS Opens a Temporary Peptide Path, but Hims Still Faces a Rulemaking Wait
HHS will temporarily exercise enforcement discretion for certain patient-specific peptide compounding while it writes a formal rule. The policy creates an option for Hims, but it does not guarantee an immediate launch or repair compressed margins.
A new federal policy gives qualifying compounding pharmacies a temporary path to prepare certain peptides while formal rulemaking proceeds. For Hims & Hers, the change may expand future product options, but it is not the same as final approval or an immediate commercial launch.
The Department of Health and Human Services said it will use enforcement discretion for compounding under Section 503A of the Food, Drug, and Cosmetic Act involving six peptide bulk substances. The policy applies only while HHS develops the formal list through rulemaking and requires conditions involving ingredient quality, manufacturing, safety reporting, labeling and patient-specific prescriptions.
That wording matters. Enforcement discretion describes when the government does not intend to take action; it does not approve the peptides as drugs, eliminate pharmacy obligations or guarantee that the final rule will include the same substances on the same terms. The notice also allows public comments after Federal Register publication.
The source report says Hims has previously indicated that it would wait for final rulemaking before selling peptides still under review. If that position holds, the temporary policy may not generate near-term revenue. The company has separately discussed NAD+, sermorelin and glutathione under existing compounding pathways, which should not be confused with automatic permission to commercialize every substance covered by the new notice.
The financial context explains the market's interest. Hims reported second-quarter revenue of $753.2 million, up 38% from a year earlier, but gross margin fell to 64% from 76%. The company recorded an $86.3 million net loss, compared with $42.5 million of net income a year earlier. Adjusted EBITDA declined to $60.3 million from $82.2 million, and free cash flow was negative $68.2 million.
Management raised full-year revenue guidance to $3.1 billion to $3.3 billion but set adjusted EBITDA guidance at $275 million to $325 million. That combination shows the tradeoff: branded weight-loss products and international growth can increase sales while lowering consolidated margin.
A vertically integrated peptide offering could improve economics if Hims can manufacture compliant products at attractive cost and acquire patients efficiently. Neither condition is established by the enforcement notice. The company still needs a final regulatory framework, product-specific operating decisions and evidence that demand converts into profitable subscriptions.
The next decisive information will be Hims' third-quarter margin and any formal statement about whether it will use the temporary policy. For now, the HHS action creates regulatory optionality. It does not remove the rulemaking risk or solve the margin compression already visible in the financial statements.